Security key
98420X103
X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (XFOR)
CUSIP: 98420X103
Q2 2020 13F Holders as of 30 Jun 2020
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 10,703,549
- Total 13F value
- $99,748,639
- Share change
- -212,951
- SEC-reported price per share
- $9.32
- Number of holders
- 54
- Value change
- -$2,349,709
- Number of buys
- 32
- Number of sells
- 19
- Shares outstanding
- 94,372,096
Holder snapshot
6 signals
Security identity
1 source field
Report period
Q2 2020
Institutions
54
Top holders
10
XFOR full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2020
Previous quarter: Q1 2020
X4 Pharmaceuticals, Inc SEC filings
X4 Pharmaceuticals, Inc company facts
Broader feeds
Reporting periods
Holder history for CUSIP 98420X103
Recent filing periods:
Ownership snapshot
Top reported holders of XFOR - X4 PHARMACEUTICALS, INC. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Bain Capital Life Science...
Disclosed value leader
Bain Capital Life Science...
Comparable rows
15/15
Latest evidence
31 Mar 2020
13F
Lead comparable stake: 1.7%
Showing 1-6 of 15 holder rows.
Quick read
Bain Capital Life Sciences Investors, LLC leads the comparable SEC ownership view at 1.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
Bain Capital Life Sciences Invest...
1.7%
BVF INC/IL
1.2%
ORBIMED ADVISORS LLC
1.2%
BlackRock Finance, Inc.
0.93%
SPHERA FUNDS MANAGEMENT LTD.
0.93%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Bain Capital Life Sciences Investors, LLC |
13F
Company
|
1.7%
|
$16,485,000
1,648,485 shares
|
— | 31 Mar 2020 |
| BVF INC/IL |
13F
Company
|
1.2%
|
$11,717,000
1,171,728 shares
|
— | 31 Mar 2020 |
| ORBIMED ADVISORS LLC |
13F
Company
|
1.2%
|
$10,865,000
1,086,493 shares
|
— | 31 Mar 2020 |
| BlackRock Finance, Inc. |
13F
Company
|
0.93%
|
$8,755,000
875,549 shares
|
— | 31 Mar 2020 |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
Company
|
0.93%
|
$8,732,000
873,215 shares
|
— | 31 Mar 2020 |
| VANGUARD GROUP INC |
13F
Company
|
0.78%
|
$7,391,000
739,048 shares
|
— | 31 Mar 2020 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2020
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
54
Shares
10,703,549
Rows available
54
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2020 vs Q1 2020 Across Filers
Q1 2020 holders
49
Q2 2020 holders
54
Holder diff
5
| Investor | Q1 2020 Shares | Q2 2020 Shares | Share Diff | Share Chg % | Q1 2020 value | Q2 2020 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend